A M Mansour1. 1. Department of Ophthalmology, American University of Beirut, PO Box 113-6044, Beirut, Lebanon. dr.ahmad@cyberia.net.lb
Abstract
AIMS: To describe the use of subconjunctival bevacizumab or ranibizumab, an approved antivascular endothelial growth factor for wet macular degeneration, in halting the inflammation of a pterygium or a partially excised pterygium. METHODS: Case reports. RESULTS: Prompt regression of conjunctival microvessels in the pterygial bed was documented 1 week after a single subconjunctival injection of ranibizumab (one case) or bevacizumab (two cases). No side-effects were noted over 13 months of follow-up in the first case, 6 months in the second case and 1 month in the third case. CONCLUSION: Selective blockade of vascular endothelial growth factor was effective in causing regression of conjunctival microvessels in three eyes with inflamed pterygium or residual pterygia.
AIMS: To describe the use of subconjunctival bevacizumab or ranibizumab, an approved antivascular endothelial growth factor for wet macular degeneration, in halting the inflammation of a pterygium or a partially excised pterygium. METHODS: Case reports. RESULTS: Prompt regression of conjunctival microvessels in the pterygial bed was documented 1 week after a single subconjunctival injection of ranibizumab (one case) or bevacizumab (two cases). No side-effects were noted over 13 months of follow-up in the first case, 6 months in the second case and 1 month in the third case. CONCLUSION: Selective blockade of vascular endothelial growth factor was effective in causing regression of conjunctival microvessels in three eyes with inflamed pterygium or residual pterygia.
Authors: Giulio Ferrari; Mohammad H Dastjerdi; Andre Okanobo; Sheng-Fu Cheng; Francisco Amparo; Nambi Nallasamy; Reza Dana Journal: Cornea Date: 2013-07 Impact factor: 2.651